Vital Regroups after Bio-Artificial Liver fails in Phase III
This article was originally published in Scrip
Executive Summary
Vital Therapies, Inc. is assessing its options for moving forward with its stem cell-based bio-artificial liver therapy, ELAD, after the VTI-208 pivotal trial failed to meet its primary endpoint.